A new metasurface spectral AI chip enables rapid, accurate diagnosis of meibomian gland dysfunction (MGD) from tissue samples, achieving 96.22% accuracy.
Key Details
- 1Researchers from Peking Union Medical College Hospital and Tsinghua University developed a compact optical AI chip for MGD diagnosis.
- 2The AI chip integrates a spectral convolutional neural network (SCNN) directly onto a CMOS imaging sensor.
- 3Pathological tissue sections from MGD patients and controls were rapidly analyzed, producing spectral feature maps in tens of milliseconds.
- 4The chip identifies MGD with 96.22% accuracy, outperforming conventional RGB image analysis (84%) and matching hyperspectral imaging.
- 5Distinct spectral signatures corresponded with disease severity and biochemical changes in gland tissue.
- 6The device is CMOS-fabricated, enabling potential clinical integration for real-time, objective ocular assessment.
Why It Matters
This innovation demonstrates the power of combining metasurface optics and AI for rapid, objective tissue diagnostics—reducing reliance on subjective clinical assessment and paving the way for real-time, in-sensor medical AI applications.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.